Kinovate Life Sciences, Inc. and NittoDenko Corporation Announce SuccessfulDevelopment of NittoPhase® HL HighLoading Solid Support for OligonucleotideSynthesis
NittoPhase® HL Loaded up to 400umol/g delivers Market Leading Economies to Reduce Synthesis Costs and Increase Yields
Kinovate Life Sciences, Inc, the market leader in solid support for oligonucleotide synthesis, will be announcing the successful development of its next generation high loading polymeric solid support product NittoPhase®HL for oligonucleotide synthesis at the TIDES meeting commencing in Las Vegas on May 17th. In thorough testing NittoPhase®HL loaded at 400umol/g and 240umol/g has shown consistently strong yields and excellent full length purity when utilized for DNA and RNA synthesis respectively. The new product is scheduled to be commercially launched in the first half of 2010 at the completion of scaleup test production.
Through utilization of the unparalleled polymer synthesis and R&D capabilities of Nitto Denko Corporation, and the worldwide marketing and customer support operations of Kinovate Life Sciences, this new product promises to deliver potentially significantly improved technical and economic outcomes for all segments of the oligonucleotide industry. Solid support is the base structure used in the synthesis of oligonucleotides, including diagnostic probes and primers, antisense including RNAi, microRNA, DNA-based and aptamer drugs and represents a substantial portion of the cost to manufacture these oligonucleotides. The market leading loading capacity of NittoPhase®HL results in significantly improved yields per gram of material with superior purity, allowing users to realize significant cost savings with no compromise in quality.
“NittoPhase®HL is simply the finest solid support product developed to date. No technology has been able to offer these kinds of high loadings, yields and full length purities. We are extremely excited at the results we have seen in testing to date and expect to be able to deliver this product at a price that will make a significant impact on per micromole costs for our customers. Following on from the extraordinary success of our original NittoPhase® Solid Support product, which has fast become well established as the market leading solid support in the therapeutic oligonucleotide industry, NittoPhase®HL will cement Kinovate’s position as the market leader in this field,” stated Dr. Kenji Matsumoto, President of Kinovate Life Sciences, Inc.
